NCT01498718View on ClinicalTrials.gov

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

PHASE1CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

DNA vaccine

VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.

BIOLOGICAL

TIV

2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Trial Locations (4)

30030

Hope Clinic of the Emory Vaccine Center, Decatur

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

63104

St. Louis University - Doisy Research Center, St Louis

77030

Baylor College of Medicine, Houston

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01498718 - Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone | Biotech Hunter | Biotech Hunter